| Rahi: | |
|---|---|
E tika ana mo te haumanu - ko te ALI i whakaawehia e te LPS he rite tonu te ahua o te ALI/ARDS i te tangata me te mumura whakapeka, te kuhu leukocyte, me te edema pulmonary.
Nga pito matawhānui - Te tatau pūtau BALF (lymphocytes, neutrophils, macrophages), cytokine profiling (MCP-1, IL-6, IL-10), histopathology pūkahukahu (HE, IHC), aromatawai edema pulmonary (makuku/maroke ōwehenga).
Ma te miihini - Ka whakahohehia e te LPS te tohu tohu TLR4, te whakaoho i te huarahi NF-κB me te kaha o te urupare mumura, te whakaata i te whara o te pukupuku Gram-negative sepsis-induced.
Te uara o te whakamaoritanga - He pai mo te whakamatautau i nga raau taero anti-inflammatory, cytokine inhibitors, neutrophil elastase inhibitors, me nga rongoa-a-rorohiko.
Nga kohinga raraunga kua rite IND - Ka taea te whakahaere rangahau i runga i nga tikanga o te GLP.
LPS Induced ALI Model in BALB/c Kiore
• Te whakamatautau kaha o nga raau taero anti-inflammatory (corticosteroids, NSAIDs), cytokine inhibitors (anti-IL-6, anti-TNF-α), me te neutrophil elastase inhibitors
• Aromatawai i te whakamaaramatanga o te mesenchymal stem cell (MSC) me nga maimoatanga e pa ana ki te vesicle extracellular
• Te whakamanatanga whainga mo te tohu tohu TLR4, te ara NF-κB, me nga rekereke mumura
• Te kitenga o te tohu koiora (kotaha pūtau BALF, waitohu cytokine, tohu whara pūkahukahu)
• Maatauranga rongoora me te paitini whakaahei IND
Tawhā |
Whakatakotoranga |
Momo/Riki |
BALB/c kiore |
Tikanga whakauru |
Intratracheal, intranasal, intraperitoneal whakahaere o lipopolysaccharide (LPS, 5-10 mg/kg) |
Te roanga ako |
Ake: 6–48 haora i muri i te whakahaerenga o te LPS |
Nga pito mutunga matua |
Tatau pūtau BALF (tapeke me te rerekētanga: neutrophils, macrophages, lymphocytes), nga taumata cytokine BALF (MCP-1, IL-6, IL-10 na ELISA), te histopathology pūkahukahu (he whakapouri me te whiu whara pūkahukahu), immunohistochemistry (IHC) mo nga tohu inflammatory, pūkahukahu mākū/maroke tauwehenga taumaha (he ahotea oxidative MPO) |
Mōkihi Raraunga |
Raraunga mata, pūrongo tātari, tatau pūtau BALF, hua ELISA, kiriata hītori (HE, IHC), bioinformatics (he kōwhiri) |
P: Me pehea te LPS e whakararu ai i te whara o te pukahukahu i roto i nga kiore?
A: Ka herea e te LPS ki te TLR4 i runga i nga pūtau aukati, te whakahohe i nga huarahi NF-κB me te MAPK, e arai ana ki te urupare inflammatory pakari me te tuku cytokine (IL-6, TNF-α, MCP-1), te whakauru neutrophil ki nga ngongo, te piki haere o te vascular permeability, me te kino o te alveolar, e tino rite ana ki te Gram-induced sepsis kino kino.
Q: He aha nga tino rite ki te tangata ALI/ARDS?
A: Ko te tauira e whakaatu ana i te whakaurunga neutrophil, nga cytokines pro-inflammatory teitei, te edema pulmonary, me nga ahuatanga histopathological (te matotoru o te alveolar, te hanga o te membrane hyaline) he rite ki te tangata ALI / ARDS.
P: Ka taea te whakamahi i tenei tauira mo nga rangahau whakaahei IND?
A: Ae. Ka taea te whakahaere rangahau i runga i nga tikanga GLP mo nga tukunga ture (FDA, EMA).
P: Ka tukuna e koe nga tikanga ako kua whakaritea (hei tauira, he rereke nga pota LPS, nga huarahi whakahaere, nga waahi wa)?
A: Tino. Ko ta matou roopu putaiao e whakarite ana i nga tikanga whakangao LPS, nga huarahi whakahaere, me nga tātaritanga mutunga ki to kaitono tarukino motuhake.
